# Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

> **NCT01316458** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Prostatic Neoplasm
- Genital Neoplasms, Male
- Neoplasms, Abdominal
- Urogenital Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Antineoplastic Agents
- Imatinib

## Interventions

- **DRUG:** STI571 (Glivec®)

## Key facts

- **NCT ID:** NCT01316458
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316458, "Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01316458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*